SI-Bone Inc (NASDAQ:SIBN) has been given an average rating of “Buy” by the six brokerages that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $24.75.
SIBN has been the topic of a number of recent analyst reports. ValuEngine raised SI-Bone from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Zacks Investment Research raised SI-Bone from a “sell” rating to a “hold” rating in a report on Saturday, July 6th.
NASDAQ:SIBN opened at $19.09 on Tuesday. The firm has a market cap of $465.72 million and a P/E ratio of -26.89. The company has a current ratio of 12.00, a quick ratio of 11.55 and a debt-to-equity ratio of 0.50. The stock’s 50 day simple moving average is $19.06 and its 200-day simple moving average is $18.23. SI-Bone has a 12-month low of $14.08 and a 12-month high of $23.03.
SI-Bone (NASDAQ:SIBN) last announced its quarterly earnings data on Tuesday, August 6th. The company reported ($0.35) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.40) by $0.05. SI-Bone had a negative return on equity of 84.84% and a negative net margin of 46.59%. The firm had revenue of $16.32 million for the quarter. Research analysts forecast that SI-Bone will post -1.4 EPS for the current fiscal year.
In other SI-Bone news, CFO Laura Francis sold 2,518 shares of the business’s stock in a transaction on Tuesday, June 25th. The stock was sold at an average price of $17.92, for a total transaction of $45,122.56. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder Skyline Venture Partners V. Lp sold 400,000 shares of the business’s stock in a transaction on Monday, August 12th. The stock was sold at an average price of $18.25, for a total value of $7,300,000.00. The disclosure for this sale can be found here. Insiders have sold 755,217 shares of company stock worth $14,098,227 in the last ninety days. 38.80% of the stock is currently owned by corporate insiders.
A number of institutional investors and hedge funds have recently bought and sold shares of SIBN. Legal & General Group Plc purchased a new stake in SI-Bone during the fourth quarter worth $27,000. Bank of Montreal Can purchased a new stake in shares of SI-Bone in the second quarter valued at $28,000. Private Ocean LLC purchased a new stake in shares of SI-Bone in the second quarter valued at $131,000. Deutsche Bank AG purchased a new stake in shares of SI-Bone in the fourth quarter valued at $227,000. Finally, Citadel Advisors LLC purchased a new stake in shares of SI-Bone in the second quarter valued at $272,000. Institutional investors own 42.86% of the company’s stock.
SI-Bone Company Profile
SI-BONE, Inc, a medical device company, develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. It offers iFuse, an implant system to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain. The company was founded in 2008 and is headquartered in Santa Clara, California.
Receive News & Ratings for SI-Bone Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SI-Bone and related companies with MarketBeat.com's FREE daily email newsletter.